Accelerated Underwriting Mortality Experience in 2026: Early Results and Trends

The life insurance industry has spent the better part of a decade building accelerated underwriting programs, promising faster decisions and lower costs. The harder question was always whether skipping labs and fluid testing would show up in the mortality numbers. That question is no longer theoretical. Enough time has passed, enough policies have been issued, and enough claims have come through that the accelerated underwriting mortality experience data is starting to tell a real story.

The short version: mortality slippage exists, it's measurable, and it varies wildly depending on how a program was designed. But the carriers who invested in monitoring and recalibration are seeing results that hold up against traditional underwriting paths. The ones who launched a program and walked away are in a different position entirely.

Gen Re's 2025 Next Gen Analytics study, covering over 14,000 policies and nearly $10 billion in face amount, found that mortality slippage in accelerated underwriting programs stabilized at approximately 12.3% after years of upward pressure. The data stretches back to 2019, making it one of the longest-running mortality studies specific to accelerated programs.

What the mortality data actually shows

Mortality slippage measures the gap between what a carrier expected (based on risk class assignments from traditional underwriting) and what actually happened when those same applicants were classified through an accelerated path. If an accelerated program assigns someone to Preferred Plus who would have been Standard under full underwriting, that difference eventually shows up in claims.

Munich Re's mortality slippage study, published in collaboration with the Society of Actuaries in 2024, defined slippage as "the implied mortality load relative to full underwriting mortality due to risk class misclassification in the accelerated underwriting process." They calculated it on a present value of future claims basis, which means the number captures not just deaths that already happened but projected future cost based on current misclassification patterns.

The Munich Re analysis found that slippage concentrates in specific segments. Lower face amounts—policies under $250,000—showed higher slippage than larger policies. This makes intuitive sense. Larger policies tend to trigger additional data pulls (MIB, prescription history, motor vehicle records) that catch risk factors the accelerated algorithm might miss on smaller cases. Tobacco users also showed elevated slippage compared to non-tobacco classes.

How WTW's TOAMS 6 study fits in

Willis Towers Watson released their TOAMS 6 (Trends Over Actual-to-Expected Mortality Study) results in January 2026. While TOAMS isn't specific to accelerated underwriting, it provides the baseline against which accelerated mortality should be measured. The study found persistent mortality differences by risk class and age in U.S. individual life insurance, with nonsmokers showing sustained mortality variation that carriers need to account for in any program that relies on algorithm-based risk classification.

The TOAMS 6 data matters here because accelerated underwriting doesn't exist in a vacuum. If baseline mortality assumptions are shifting—and post-pandemic, they clearly are—then evaluating accelerated program performance requires understanding what "normal" looks like in 2026. It doesn't look like 2019 anymore.

Comparing mortality monitoring approaches

Different carriers track mortality slippage differently, and the method matters. The table below compares the main approaches in use.

Monitoring approach	What it measures	Data maturity needed	Strengths	Limitations
Actual-to-expected (A/E) ratios	Claims vs pricing assumptions	5+ years of in-force data	Direct, well-understood	Slow to develop statistical credibility
Shadow underwriting studies	Accelerated vs full UW decisions on same cases	Immediate (parallel process)	Fast feedback loop	Expensive to run at scale
Predictive model backtesting	Model accuracy on historical cohorts	2-3 years of model output	Identifies drift early	Doesn't capture unknown unknowns
Risk class migration analysis	How classifications shift over time	3+ years	Catches systematic bias	Requires granular tracking infrastructure
Claims deep-dives	Individual claim investigation	Ongoing	Rich qualitative insight	Small sample, selection bias
Third-party benchmarking (Gen Re, Munich Re)	Cross-carrier comparison	Varies	Industry context	Anonymized, limited granularity

Gen Re's 2024 accelerated underwriting survey found that 81% of carriers reported meeting their accelerated underwriting goals. Only one company said it exceeded goals, and 16% reported missing them. The survey also showed that mortality slippage continues to rank among the top concerns, alongside throughput rates and data source effectiveness.

Where the results diverge

Not every accelerated program is producing the same mortality outcomes. The spread between well-managed and poorly-managed programs is significant, and it comes down to a few design decisions made early on.

Programs with active monitoring

Carriers that built mortality monitoring into their accelerated programs from day one—running shadow studies, tracking risk class migration, and recalibrating eligibility criteria based on emerging data—are seeing slippage numbers in the single digits. These programs typically also have dedicated actuarial resources assigned to accelerated underwriting, separate from the traditional book.

RGA's published research on program evolution documented that carriers who periodically revisit and expand eligibility criteria based on mortality experience data see improvements without measurable deterioration in actual-to-expected ratios. The key word is "periodically." Annual review cycles work. Set-and-forget doesn't.

Programs without it

The carriers struggling with mortality slippage tend to share a pattern: they launched an accelerated program with conservative eligibility thresholds, never updated them, and didn't invest in ongoing mortality monitoring. Their programs technically "work" in the sense that policies get issued faster, but nobody can say with confidence whether the mortality is acceptable because nobody is measuring it rigorously.

Munich Re's analysis flagged this as a systemic issue. Programs without structured monitoring often don't discover slippage problems until claims data matures three to five years later, by which point the in-force block already carries the embedded cost.

The role of data sources in mortality outcomes

Mortality slippage doesn't come from the concept of accelerated underwriting itself. It comes from the specific data sources used to replace the information that labs and fluid testing would have provided.

The Gen Re 2024 survey tracked which data sources carriers rely on most heavily:

• Prescription history (Rx): used by nearly all programs, and consistently rated as the most valuable single data source
• Motor vehicle records (MVR): still widely used but declining in perceived value
• MIB (Medical Information Bureau): standard, but limited by what previous carriers reported
• Electronic health records (EHR): growing in adoption, with carriers reporting improved risk classification when EHR data is available
• Credit-based models: controversial but still in use at some carriers
• Clinical lab databases: emerging as a supplementary data source for programs that want lab-adjacent data without requiring the applicant to visit a clinic

The carriers seeing the best mortality results tend to use four or more data sources in combination, rather than relying heavily on any single one. Each source has blind spots. Rx history misses applicants who don't fill prescriptions. MVRs miss applicants who don't drive. EHR data isn't available for everyone. Layering sources compensates for individual gaps.

There's a newer data category entering the conversation: contactless biometric data captured through smartphone cameras using remote photoplethysmography (rPPG). This approach captures heart rate, respiratory rate, and other vital signs without any physical equipment. It's still early, but some carriers are evaluating whether real-time biometric signals could fill the gap left by eliminating fluid testing. Companies like Circadify are building this capability specifically for insurance workflows.

What the reinsurance market is saying

Reinsurers have a direct financial stake in accelerated underwriting mortality outcomes, and their appetite for covering these programs shapes what carriers can offer. The reinsurance perspective in 2026 is more nuanced than it was three years ago.

Munich Re and Gen Re both publish mortality studies partly to signal their expectations to the market. When Gen Re reports that slippage has stabilized at 12.3%, that number becomes a benchmark. Carriers with slippage above that level face harder conversations with their reinsurance partners. Carriers below it have leverage.

The reinsurance community's main ask in 2026 is transparency. Reinsurers want to see structured mortality monitoring, not just aggregate A/E ratios but granular breakdowns by risk class, face amount band, data sources used, and program vintage. Carriers who can provide this level of detail tend to get better treaty terms. Those who can't are increasingly being asked to provide it before renewal.

We covered the dynamics of building reinsurer confidence in digital underwriting programs in a previous analysis.

Current research and evidence

Several research efforts are shaping the 2026 understanding of accelerated underwriting mortality:

The Society of Actuaries continues to fund research into mortality implications of simplified and accelerated underwriting. Their Product Development Section published a detailed analysis in August 2024 by Daniel Seeman of Munich Re, examining mortality slippage methodology and monitoring best practices. That paper established much of the analytical framework that carriers and reinsurers now use to evaluate program performance.

Gen Re's Next Gen Underwriting Survey, now in its fifth year, provides the largest cross-carrier dataset on accelerated underwriting adoption and outcomes. The 2025 edition, released in March 2026, reported on over 14,000 policies and showed that mortality slippage has stopped increasing after several years of upward trends. The stabilization suggests that the industry's collective adjustments to eligibility criteria, data sourcing, and monitoring are having an effect.

WTW's TOAMS 6 study, released in January 2026, provides context for individual life mortality trends more broadly. Post-pandemic mortality patterns continue to influence baseline expectations, and any evaluation of accelerated underwriting performance needs to account for these shifts. Comparing accelerated program mortality to pre-pandemic baselines gives a misleading picture.

What comes next for accelerated underwriting mortality

The next two years will bring more clarity. Many programs launched between 2019 and 2021 are now reaching the five-to-seven-year maturity window where mortality data starts to gain real statistical credibility. Carriers that invested in tracking infrastructure will finally have actionable numbers. Those that didn't will be doing forensic work.

Three trends are likely to shape the mortality conversation through 2028:

First, more carriers will adopt multi-source data strategies rather than relying on prescription history alone. The Gen Re data strongly suggests that program-level mortality outcomes correlate with the number and quality of data sources used.

Second, real-time biometric screening is moving from experimental to pilot-stage at several carriers. The ability to capture vital signs at the point of application—without scheduling a nurse visit or mailing a kit—could add a new layer of health data that current accelerated programs lack entirely.

Third, reinsurer expectations around mortality monitoring will harden into treaty requirements. What was once a recommendation ("you should track risk class migration") will become a condition of coverage.

Frequently asked questions

What is mortality slippage in accelerated underwriting?

Mortality slippage measures the additional mortality cost that results from risk class misclassification in an accelerated underwriting program compared to traditional full underwriting. If an applicant gets assigned to a better risk class than they would have received under full underwriting, the carrier takes on more mortality risk than priced for. Slippage quantifies that gap on a present value basis.

How long does it take to get meaningful mortality data from an accelerated program?

Most actuaries consider three to five years the minimum for early directional signals, with five to seven years needed for statistically credible results. Shadow underwriting studies can provide earlier feedback on classification accuracy, but actual claims experience takes time to develop. Programs launched in 2019 are just now entering the window where their mortality data becomes truly useful.

Is accelerated underwriting mortality worse than traditional underwriting?

Not necessarily. Well-designed programs with active monitoring show modest slippage that can be offset by pricing adjustments and volume gains. The Gen Re 2025 study found that slippage stabilized at around 12.3% across their dataset, which many carriers and reinsurers consider within acceptable bounds. Poorly monitored programs with narrow data sourcing tend to show worse results.

What data sources matter most for controlling mortality outcomes?

Prescription history remains the single most valuable data source according to Gen Re's survey data. However, programs using four or more data sources in combination tend to produce better mortality outcomes than those relying heavily on any single source. Electronic health records and clinical lab databases are gaining traction as supplementary sources that improve risk classification accuracy.